Dianthus Therapeutics, Inc. (DNTH)
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
$82.38-0.39%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
Research Workspace
Put DNTH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — EPS reaches at least $0.85 by June 2026: Diluted EPS: $-0.90 per share.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 32%, softest on free-cash-flow margins.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 38% in its worst 12-month stretch.
View RiskDNTH depends on rapid sales growth, although its recent financial performance is weak and its earnings remain negative. Revenue grew 295% year over year in Q2 FY2026, and diluted EPS beat consensus at negative $0.90. DNTH trades at 251 times sales versus a 10-times peer median, and 343 times its own historical multiple. The market is pricing in more growth than our forecast. Our model puts the next-quarter miss probability near 36%. The standing thesis is Broken because diluted EPS missed the stated June 2026 pillar. Peer multiples imply a price about 37% above where it trades; this read is provisional.
Trailing returns as of 2026-10-30. DNTH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering DNTH (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for DNTH in the last 4 months.
Continue this research
Compare DNTH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| DNTH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put DNTH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Maintain strong cash position with runway into 2030
Insider selling may indicate concerns about cash position.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $82.38
The last 12 months of price, then the range of analyst 12-month targets from today’s $82.38.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Sanofi's trial failure raises concerns about competitive landscape.
Stock drop indicates market concerns over competitive positioning.
Positive outlook on product pipeline supports investment thesis.
Executive stock sale raises concerns about insider confidence.
Positive analysis highlights multiple growth opportunities.